TY - JOUR
T1 - Impact of Atrial Fibrillation on Outcomes of Aortic Valve Implantation
AU - Ahmed, Raheel
AU - Sawatari, Hiroyuki
AU - Deshpande, Saurabh
AU - Khan, Hassan
AU - Rui, Providencia
AU - Khanji, Mohammed Y.
AU - Sherif, Akil A.
AU - Jaliparthy, Keerthi
AU - Reddy, Sathish
AU - Nkomo, Vuyisile T.
AU - Manjunath, Cholenahally N.
AU - Yong-Mei, Cha
AU - Somers, Virend K.
AU - Brady, Peter A.
AU - Chahal, Anwar A.
AU - Padmanabhan, Deepak
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1/15
Y1 - 2022/1/15
N2 - [Formula presented] New or preexisting atrial fibrillation (AF) is frequent in patients undergoing aortic valve replacement. We evaluated whether the presence of AF during transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) impacts the length of stay, healthcare adjusted costs, and inpatient mortality. The median length of stay in the patients with AF increased by 33.3% as compared with those without AF undergoing TAVI and SAVR (5 [3 to 8] days vs 3 [2 to 6] days, p <0.0001 and 8 [6 to 12] days vs 6 [5 to 10] days, p <0.0001, respectively). AF increased the median value of adjusted healthcare associated costs of both TAVI ($46,754 [36,613 to 59,442] vs $49,960 [38,932 to 64,201], p <0.0001) and SAVR ($40,948 [31,762 to 55,854] vs $45,683 [35,154 to 63,026], p <0.0001). The presence of AF did not independently increase the in-hospital mortality. In conclusion, in patients undergoing SAVR or TAVI, AF significantly increased the length of stay and adjusted healthcare adjusted costs but did not independently increase the in-hospital mortality.
AB - [Formula presented] New or preexisting atrial fibrillation (AF) is frequent in patients undergoing aortic valve replacement. We evaluated whether the presence of AF during transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) impacts the length of stay, healthcare adjusted costs, and inpatient mortality. The median length of stay in the patients with AF increased by 33.3% as compared with those without AF undergoing TAVI and SAVR (5 [3 to 8] days vs 3 [2 to 6] days, p <0.0001 and 8 [6 to 12] days vs 6 [5 to 10] days, p <0.0001, respectively). AF increased the median value of adjusted healthcare associated costs of both TAVI ($46,754 [36,613 to 59,442] vs $49,960 [38,932 to 64,201], p <0.0001) and SAVR ($40,948 [31,762 to 55,854] vs $45,683 [35,154 to 63,026], p <0.0001). The presence of AF did not independently increase the in-hospital mortality. In conclusion, in patients undergoing SAVR or TAVI, AF significantly increased the length of stay and adjusted healthcare adjusted costs but did not independently increase the in-hospital mortality.
UR - http://www.scopus.com/inward/record.url?scp=85118732891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118732891&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2021.09.036
DO - 10.1016/j.amjcard.2021.09.036
M3 - Article
C2 - 34772477
AN - SCOPUS:85118732891
SN - 0002-9149
VL - 163
SP - 50
EP - 57
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -